Proteins and Peptides
22 October 2014
Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes22 October 2014
Synageva BioPharma Starts Rolling Submission Of A Biologics License Application To The FDA For Sebelipase Alfa20 October 2014
Genervon Announces ALS and PD Phase 2a Trial Results17 October 2014
China Biologic Receives Approval for Commercial Manufacturing of Human Prothrombin Complex Concentrate at Shandong Taibang Facility16 October 2014
Allegro Ophthalmics Begins Phase 2 Clinical Trial of Luminate® (ALG-1001) for the Treatment of Diabetic Macular Edema10 October 2014
FDA Approves VELCADE® (bortezomib) for Injection for Previously Untreated Patients with Mantle Cell Lymphoma10 October 2014
ORBACTIVTM (Oritavancin) Phase 3 SOLO II Trial Results Published in the Journal Clinical Infectious Diseases9 October 2014
N8 Respiratory Presents Data Demonstrating Antimicrobial Efficacy of CSA-13 Against Psuedomonas Aeruginosa Biofilm8 October 2014
Trevena Announces Early Completion of Enrollment of Phase 2a/b Study of TRV130 in Postoperative Pain6 October 2014
Galderma Initiates U.S. Study of Novel Muscle Relaxant for Aesthetic Dermatology and Cosmetic Surgery3 October 2014
European Commission Grants Marketing Authorisation to Humalog® 200 units/ml KwikPen™ Insulin3 October 2014
APT Therapeutics’ Apyrase-Based Investigational Drug Minimizes Damage from Heart Attack without Increasing Hemorrhage2 October 2014
Revance Therapeutics Provides Update on RT001 Clinical Program for the Lead Indication for Crow’s Feet Lines1 October 2014
ERYTECH Reports Positive Top-Line Phase III Results from Clinical Study with GRASPA® in Acute Lymphoblastic Leukemia26 September 2014
Novartis drug Signifor® LAR recommended by CHMP for EU approval to treat patients with rare hormonal disorder acromegaly26 September 2014
Approval for Sustained-Duration G-CSF Product G-Lasta® in Japan25 September 2014
Celldex Therapeutics Initiates Pilot Study of CDX-301 in Allogeneic Hematopoietic Stem Cell Transplantation25 September 2014
Blaze Bioscience Announces Initiation of Phase 1b Brain Cancer Program for Tumor PaintTM BLZ-10023 September 2014
Novaliq GmbH Reports Positive Results from CyclASol® (Cyclosporin Solution) Eye Drops Repeated and Ascending Dose Phase 1 Study22 September 2014
New Xultophy® (IDegLira) data show rapid and predictable glycaemic improvements in people with type 2 diabetes22 September 2014
Novo Nordisk – Xultophy® (IDegLira) approved in EuropeNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports